Articles about 'drug discovery'

Cambridge researchers are looking at ways that AI can transform everything from drug discovery to Alzheimer's diagnoses to GP consultations.

Antibiotics, antivirals, vaccinations and anti-inflammatory medication are associated with reduced risk of dementia, according to new research that looked at health data from over 130 million individuals.

What excites Steve Jackson is understanding how biology works and why it sometimes goes wrong. But what galvanises him is knowing there are people alive today as a result of his discovery of how to create a cancer drug.

Researchers have used artificial intelligence techniques to massively accelerate the search for Parkinson’s disease treatments.

Researchers have developed a platform that combines automated experiments with AI to predict how chemicals will react with one another, which could accelerate the design process for new drugs.

The facility, based at the Milner Therapeutics Institute, will support the discovery of new medicines and diagnostics for chronic diseases by applying advanced biological and technological tools, including CRISPR gene editing.

Researchers have developed a method to identify new targets for human disease, including neurodegenerative conditions such as Alzheimer’s disease.

Vector Bioscience has received a £2.2 million investment to help it take forward its drug delivery platform designed to make RNA cancer therapies more effective.

A University of Cambridge spin-out company from the Cavendish Laboratory, combines materials engineering and cell biology to help biopharma companies make better medicines, faster. It announced today that it has closed a £2.14 million seed funding round.

Cambridge's Experimental Medicine Initiative, working with AstraZeneca and GSK, is training specialists who can work out at an earlier stage of clinical trials if a treatment is likely to succeed.